Literature DB >> 25961535

Epigenetic regulation of hepatic tumor-initiating cells.

Jia Ding, Jian Wu1.   

Abstract

Hepatocellular carcinoma (HCC) is the third most lethal cancer and resistant to common chemotherapy. Tumor-initiating cells (T-ICs) that are thought to be responsible for tumorigenesis share surface markers and signaling pathways similar to normal tissue stem cells. Identification of T-ICs and elucidation of aberrant epigenetic modulation and self-renewal pathways may provide new insights into hepatic carcinogenesis, metastasis and chemotherapeutic resistance. Histone modification, DNA methylation and microenvironmental changes are considered as key elements to promote the derivation and function of T-ICs. In this review, we intend to compare the similarity and difference between normal liver stem cells and T-ICs, and to define the intrinsic and micro-environmental factors that lead to the transformation from normal liver stem cells to hepatic T-ICs. We believe that etiology, microenvironmental alteration, epigenetic modification and epithelial-mesenchymal transition play a fundamental role in initiating the transformation. Strategies targeting signaling molecules critical in modulating these processes may offer a personalized therapy for HCC in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25961535     DOI: 10.2741/4349

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  2 in total

1.  Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice.

Authors:  Rui Yang; Qiusha Tang; Fengqin Miao; Yanli An; Mengfei Li; Yong Han; Xihui Wang; Juan Wang; Peidang Liu; Rong Chen
Journal:  Int J Nanomedicine       Date:  2015-12-07

Review 2.  Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

Authors:  Jian Wu
Journal:  Oncotarget       Date:  2016-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.